In efforts to minimize compliance issues and improve overall patient adherence, researchers are evaluating sustained-release devices and methods to extend drug delivery. The first of these (for the treatment of glaucoma) dates to the 1970s. Numerous drug delivery systems/devices are currently marketed, and many others are in development. Several sustained-release devices that are in the pipeline include topical bimatoprost ocular insert, travoprost and latanoprost punctal plugs, latanoprost-eluting contact lenses, loteprednol etabonate in an MPP, bimatoprost and travoprost intraocular implants, and drug-delivery systems inserted into the anterior chamber angle during cataract surgery.
This webcast includes discussions on traditional treatment approaches as well as newer treatment options and those nearing the end of the pipeline for FDA approval. The discussion, including case studies, focuses on the ideal patients for the sustained-delivery treatments, taking into consideration patient compliance and insurance/payment challenges.
Target audience: Eye care providers who treat patients with glaucoma.
Supported through an educational grant from Ocular Therapeutix.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Jason Bacharach, MD
Director, Glaucoma Division
California Pacific Medical Center
San Francisco, California
Medical Director & Founding Partner
North Bay Eye Associates, Inc.
Sonoma County, California
James C. Tsai, MD, MBA
President, New York Eye and Ear Infirmary of Mount Sinai
Delafield-Rodgers Professor and System Chair
Department of Ophthalmology
Icahn School of Medicine at Mount Sinai
New York City, New York
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Jason Bacharach, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Glaukos, and Ocular Therapeutics; Grant Research Support: Allergan, Glaukos, and Ocular Therapeutics. Speaker’s Bureau; Allergan, and Glaukos.
James C. Tsai, MD, MBA and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Eyenovia, ReNetxx Bio, and Smartlens.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Ocular Therapeutix.